Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01962987 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis
A Phase 3 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 3
- Development phase
- 476
- Enrollment target
NCT01962987 is a Phase 3 study that has completed, run by Actavis. The registered enrollment target is 476 participants.
The verdict
NCT01962987, a Phase 3 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 476 participants
- Enrollment target
Study Summary
To compare the relative efficacy and safety of the test formulation diclofenac sodium gel 3% (Actavis) to the marketed formulation Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms) in the treatment of the actinic keratosis
Interventions
- OTHER Placebo
- DRUG Diclofenac sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 476 participants |
| Start Date | 2013-03 |
| Est. Completion | 2013-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01962987
The ClinicalTrials.gov registry entry for NCT01962987 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 476 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01962987 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01962987 about?
NCT01962987 is a clinical study titled "A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis". To compare the relative efficacy and safety of the test formulation diclofenac sodium gel 3% (Actavis) to the marketed formulation Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms) in the treatment of the actinic keratosis
What is the current status of trial NCT01962987?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 476 participants. The study started on 2013-03. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01962987?
The interventions under investigation include: Placebo (OTHER), Diclofenac sodium (DRUG).
Who is sponsoring clinical trial NCT01962987?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.